XPeng heads into a pivotal week with a blockbuster strategic headline competing for attention against a Q1 earnings print due May 28.
The biggest story landed Wednesday evening. The Financial Times reported that XPeng is in talks to acquire a Volkswagen factory in Europe — a move that would mark the most tangible step yet in a Chinese EV maker's bid for direct manufacturing presence on the continent. The report earned a maximum-impact score of 10 on the ORTEX news feed, and it reframes the narrative around XPeng from a domestic growth story into a potential global manufacturing play. The stock has barely moved on the news as of the May 12 close at $16.16, up just 2.1% on the week and down 7.2% over the past month, suggesting the market is still processing what a deal would actually mean for the balance sheet ahead of results.
Short sellers have been trimming exposure into the print, but the lending market tells a more cautious story. Short interest fell nearly 5% over the past week to around 48.6 million shares, bringing SI as a percentage of the free float down to 6.85% — off the recent peak of roughly 7.2% touched in early May. That retreat is not a clean cover, though. Availability has collapsed to near zero: the lending pool is effectively fully utilised, at a level that has been its 52-week extreme for multiple consecutive sessions. Cost to borrow ticked back up to 1.25% from a mid-week low of 0.95%, and is running about 41% higher than a month ago. The message from the borrow market is that whatever shorts remain are holding tight — they have not quietly exited a market where borrow is this constrained.
Options positioning reads as neither aggressively bullish nor defensively hedged. The put/call ratio is 0.536, barely above its 20-day average of 0.524, with a z-score of 0.44 — about as neutral as the data gets. The 52-week range on the PCR runs from 0.36 at its most bullish to 1.02 at its most defensive, and the current reading is close to the middle of that band. Calls are comfortably outnumbering puts, but not by enough to suggest a conviction trade ahead of May 28. Peer NIO gained 3.1% on the week while LI added 5.4%, leaving XPEV as a slight laggard among the Chinese EV cohort, though the degree of divergence is modest rather than meaningful.
The Street picture has become incrementally more cautious. The most recent analyst actions of note — Barclays maintaining Underweight with a $16 target in late March, and Macquarie downgrading to Neutral with a $19 target around the same time — both pointed to near-term delivery uncertainty and margin pressure. The mean analyst price target sits at around $19–$25 across the active coverage (excluding Barclays, which is alone at the low end near the current price). The ORTEX short score of 69.5 ranks XPeng in roughly the top 30% of shorted names, with the utilisation-rank factor scoring at the top of the universe — a reflection of that fully utilised lending pool. EPS momentum over 30 days ranks in the 96th percentile, an unusually strong near-term estimate revision trend, but the 90-day momentum rank is just 4 — so the recent upgrade in estimates is new and fragile rather than established.
The last Q4 earnings event in mid-March produced a muted one-day move of -1.5%, but the five-day drift after that print reached -11.6% — the kind of lag that suggests the market can take a few sessions to fully digest XPeng results. With Q1 due May 28, the immediate catalyst sitting on the table is the Volkswagen factory report: any confirmation, denial, or pricing detail around that deal could move the stock independently of the fundamental beat-or-miss story. What to watch is whether the borrow market loosens as positions are adjusted into results, or whether availability stays pinned at current lows — the latter would mean any short-covering rally faces unusually little incremental supply.
See the live data behind this article on ORTEX.
Open XPEV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
